Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Prior to its merger, Cellect Biotechnology developed the ApoGraft platform, which aimed to improve the safety and efficacy of regenerative medicine and stem cell therapies by functionally selecting high-quality stem cells. The company had not yet commercialized any products or generated revenue before being acquired in a reverse merger by Quoin Pharmaceuticals in October 2021.[4][7]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cellect Biotechnology Ltd..